These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12646807)

  • 1. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy.
    Calmy A; Hirschel B; Hans D; Karsegard VL; Meier CA
    AIDS; 2003 Mar; 17(5):770-2. PubMed ID: 12646807
    [No Abstract]   [Full Text] [Related]  

  • 2. Thiazolidinediones in the treatment of HIV/HAART-associated lipodystrophy syndrome.
    Edgeworth A; Treacy MP; Hurst TP
    AIDS Rev; 2013; 15(3):171-80. PubMed ID: 24002201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actos (pioglitazone).
    TreatmentUpdate; 2001; 13(7):5-6. PubMed ID: 11794862
    [No Abstract]   [Full Text] [Related]  

  • 4. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
    Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
    Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome.
    Feldt T; Oette M; Kroidl A; Goebels K; Fritzen R; Kambergs J; Kappert G; Vogt C; Wettstein M; Häussinger D
    Infection; 2006 Apr; 34(2):55-61. PubMed ID: 16703293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone therapy for HIV/HAART-associated lipodystrophy syndrome could increase subcutaneous fat mass in non-lipoatrophic but not in lipoatrophic regions.
    Okada S; Konishi M; Ishii H
    BMJ Case Rep; 2016 Feb; 2016():. PubMed ID: 26917795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment.
    Magkos F; Mantzoros CS
    Metabolism; 2011 Jun; 60(6):749-53. PubMed ID: 20965525
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic approaches to combating lipoatrophy: do they work?
    Martin A; Mallon PW
    J Antimicrob Chemother; 2005 May; 55(5):612-5. PubMed ID: 15761072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study.
    Magkos F; Brennan A; Sweeney L; Kang ES; Doweiko J; Karchmer AW; Mantzoros CS
    Metabolism; 2011 Jul; 60(7):1045-9. PubMed ID: 21081243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lipodystrophic syndromes in HIV-infected patients receiving antiretroviral treatment].
    Simeoni J
    Ann Endocrinol (Paris); 2003 Dec; 64(6):490-1. PubMed ID: 15080164
    [No Abstract]   [Full Text] [Related]  

  • 11. [No improvement of lipodystrophy syndrome in an HIV-infected patient].
    Lanzafame M; Faggian F; Lattuada E; Antolini D; Concia E
    Recenti Prog Med; 2004 Jun; 95(6):312-3. PubMed ID: 15248414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity.
    ter Hofstede HJ; Burger DM; Koopmans PP
    Neth J Med; 2003 Dec; 61(12):393-403. PubMed ID: 15025414
    [No Abstract]   [Full Text] [Related]  

  • 13. Complications & side effects. Disappointing result for rosiglitazone and lipodystrophy.
    TreatmentUpdate; 2004 Mar; 16(2):7. PubMed ID: 17219670
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiretroviral therapy and the human immunodeficiency virus--improved survival but at what cost?
    Bradbury RA; Samaras K
    Diabetes Obes Metab; 2008 Jun; 10(6):441-50. PubMed ID: 17825081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
    Grinspoon S; Carr A
    N Engl J Med; 2005 Jan; 352(1):48-62. PubMed ID: 15635112
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).
    Slama L; Lanoy E; Valantin MA; Bastard JP; Chermak A; Boutekatjirt A; William-Faltaos D; Billaud E; Molina JM; Capeau J; Costagliola D; Rozenbaum W
    Antivir Ther; 2008; 13(1):67-76. PubMed ID: 18389900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV type 1-infected patients receiving highly active antiretroviral therapy.
    Asensi V; Martín-Roces E; Carton JA; Collazos J; Maradona JA; Alonso A; Medina M; Aburto JM; Martínez E; Rojo C; Bustillo E; Fernández C; Arribas JM
    Clin Infect Dis; 2004 Jul; 39(2):240-7. PubMed ID: 15307034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
    Cavalcanti RB; Raboud J; Shen S; Kain KC; Cheung A; Walmsley S
    J Infect Dis; 2007 Jun; 195(12):1754-61. PubMed ID: 17492590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management.
    Hirsch HH; Battegay M
    Infection; 2002 Oct; 30(5):293-8. PubMed ID: 12382089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients.
    Oette M; Kurowski M; Feldt T; Kroidl A; Sagir A; Vogt C; Wettstein M; Häussinger D
    J Antimicrob Chemother; 2005 Aug; 56(2):416-9. PubMed ID: 15983027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.